David W. Hartman & Cheryl W. Hartman
Virginia Tech Carilion School of Medicine in Roanoke, USA
Biography
David Hartman completed his medical training at Temple University School of Medicine in Philadelphia, PA; his psychiatric residency at the University of Pennsylvania. He is certified as an Addiction Psychiatrist and in Addiction Medicine and is a DATA 2000 waivered physician, credentialed to prescribe buprenorphine. He has been in psychiatric practice in Roanoke, VA since 1982, currently the section chief of Adult Outpatient Psychiatry with Carilion Clinic and is an Associate Professor with the Virginia Tech Carilion School of Medicine. He has created an office-based opioid treatment program at Carilion Clinic, where he has convened a team of practitioners, counselors, care coordinators, and nurses who provide comprehensive treatment services to OUD patients, along with his general psychiatric practice. Academic responsibilities include training medical students, psychiatry residents, and conducting research and quality improvement studies. His research focus has been on OUD medication-assisted treatment with pregnant women and the general adult population.
Cheryl Hartman completed her Ph.D. in Educational Psychology at Temple University. She has specialized in grantwriting, research, program development and services administration. Her field has included teen pregnancy and school dropout evidence-based programming, as well as substance use disorder prevention. At Carilion Clinic in Roanoke, VA she currently manages the adolescent addiction treatment program and the office-based opioid treatment program, ensuring evidence-based service practices. Cheryl serves on the faculty of the Virginia Tech Carilion School of Medicine and provides training to medical students and medical residents. She is project director for an SBIRT training grant, an ECHO teleconsultation project focused on OUD treatment expansion to rural/underserved communities, and is working on a replication of a manual-guided approach to group therapy with the OUD patients being served in the outpatient clinic.
Abstract
Statement of Problem: Globally in 2010 15.5 million people struggled with an opioid use disorder (OUD). OUD is a chronic, relapsing condition leading to significant morbidity and mortality. Since the advent of buprenorphine/naloxone pharmacotherapy with its US FDA approval in 2002, its use has expanded in the US and abroad. This form of medication-assisted treatment (MAT) has been found to decrease mortality and morbidity. Research on long term outcomes of buprenorphine/naloxone treatment is limited by small numbers and short duration of follow-up, leaving unanswered questions about impact of comorbidities and dosing on retention rates and patient outcomes.